Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:01 AM
Study NCT ID:
NCT00000560
Status:
COMPLETED
Last Update Posted:
2016-04-14
First Post:
1999-10-27
Brief Title:
Beta-Blocker Evaluation in Survival Trial BEST
Sponsor:
National Heart Lung and Blood Institute NHLBI
Organization:
National Heart Lung and Blood Institute NHLBI
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2005-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine if addition of a beta-blocker to standard therapy in Class III and Class IV heart failure patients reduced total mortality
Detailed Description:
BACKGROUND
Controlled and uncontrolled studies suggested that beta-blockade improves ventricular function in congestive heart failure Several trials suggested that beta-blockers may also reduce mortality In the Beta-Blocker Heart Attack Trial patients with a history of heart failure had less cardiac and sudden-death mortality than those who did not Patients with a low ejection fraction in the Cardiac Arrhythmia Suppression Trial who were treated with beta-blockade also had a reduction in mortality The Metoprolol in Dilated Cardiomyopathy trial randomized patients with dilated cardiomyopathies to treatment with metoprolol or placebo There was a trend toward reduction in a morbidity and mortality endpoint in patients treated with metoprolol but this was due entirely to a reduction in the need for cardiac transplantation Thus despite a reasonable theoretical basis and suggestive clinical studies the concept that beta-blockers reduced mortality in congestive heart failure patients was unproved
DESIGN NARRATIVE
Randomized double-blind multicenter Patients were assigned to standard therapy plus the addition of a beta-blocker bucindolol versus a placebo The primary endpoint was total mortality A radionuclide ventriculogram was performed within 60 days of randomization History physical examination clinical laboratory studies chest x-ray electrocardiogram and plasma norepinephrine levels were obtained within 14 days of randomization Patients were stratified by hospital congestive heart failure etiology ejection fraction and gender and were assigned to a treatment group by an adaptive balancing scheme biased coin randomization Patients were randomized to either placebo plus standard congestive heart failure treatment or to the beta-blocker plus standard congestive heart failure treatment and followed for a minimum of 18 months The over three year recruitment period began in May 1995 at the first 35 sites An additional 55 sites began recruitment on August 14 1995 Recruitment ended in December 1998 with the enrollment of 2708 patients
Controlled and uncontrolled studies suggested that beta-blockade improves ventricular function in congestive heart failure Several trials suggested that beta-blockers may also reduce mortality In the Beta-Blocker Heart Attack Trial patients with a history of heart failure had less cardiac and sudden-death mortality than those who did not Patients with a low ejection fraction in the Cardiac Arrhythmia Suppression Trial who were treated with beta-blockade also had a reduction in mortality The Metoprolol in Dilated Cardiomyopathy trial randomized patients with dilated cardiomyopathies to treatment with metoprolol or placebo There was a trend toward reduction in a morbidity and mortality endpoint in patients treated with metoprolol but this was due entirely to a reduction in the need for cardiac transplantation Thus despite a reasonable theoretical basis and suggestive clinical studies the concept that beta-blockers reduced mortality in congestive heart failure patients was unproved
DESIGN NARRATIVE
Randomized double-blind multicenter Patients were assigned to standard therapy plus the addition of a beta-blocker bucindolol versus a placebo The primary endpoint was total mortality A radionuclide ventriculogram was performed within 60 days of randomization History physical examination clinical laboratory studies chest x-ray electrocardiogram and plasma norepinephrine levels were obtained within 14 days of randomization Patients were stratified by hospital congestive heart failure etiology ejection fraction and gender and were assigned to a treatment group by an adaptive balancing scheme biased coin randomization Patients were randomized to either placebo plus standard congestive heart failure treatment or to the beta-blocker plus standard congestive heart failure treatment and followed for a minimum of 18 months The over three year recruitment period began in May 1995 at the first 35 sites An additional 55 sites began recruitment on August 14 1995 Recruitment ended in December 1998 with the enrollment of 2708 patients
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: